Latest Strategic Consulting Presentation

14,042 views
14,310 views

Published on

Aagami is a life sciences consulting firm based in the suburbs of Chicago offers services in Strategic Consulting,Technology Licensing and Market Intelligence ,

For Global Biotech, Pharmaceutical , Medical Devices, Consumer Health products companies, Universities, in their initiatives with US, India, Asia, Brazil, Latin America and Emerging Markets.

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
14,042
On SlideShare
0
From Embeds
0
Number of Embeds
11,917
Actions
Shares
0
Downloads
41
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Latest Strategic Consulting Presentation

  1. 1. Strategic Consulting |Technology Licensing |Market Intelligence Your Success, is our Success → Realizing Possibilities, Together ← Aagami , Inc. | 2135 City Gate Lane, Suite 300, Naperville, IL 60653 USA | P: +1-630-364-1837 | www.aagami.com Meet us at: June 6-9, 2016 | San Francisco, CA
  2. 2. 2 Aagami, Inc. A life sciences consulting firm which offers  Strategic Consulting  Technology Licensing  Market Intelligence Pharma Biotech Medical Technology & Equipment Consumer Healthcare Service Providers IP office of Universities FOR in their initiatives with US, India, Asia, Brazil, Rest of Latin America and other Emerging Markets.
  3. 3. 3 Your Needs, we Serve In-Licensing Out-Licensing Co-Development and Partnerships Raising Investments Mergers & Acquisitions Finding the Right Partners • JV and/or Distributors/ Contract Sales/Marketing/Contract Manufacturing, CRO and CRAMS providers New Market Entry Strategy/ Development
  4. 4. Doing it yourself - Challenges 4 Considerable time spent with immense value of your cost per hour Opportunity Cost Uncertainty on Results Understanding dynamics of all markets is difficult Limited connections in Target geographies
  5. 5. 5 What matters most to you in what we bring  Global Deal experience  Extensive network with Top LifeSciences companies at C levels  Deep Understanding of business and socio-cultural differences in ways of working  Aagami Partners bring value of combined experience of over 150 years  Focus on client needs, objectives, success and work as an extension of client’s own team.
  6. 6. 6 Many companies such as yours have benefitted from our services  Licensing and Co-Development partnership for Novel Protein Therapeutic Platform of a German company; Deals done with 2 Major Pharma.  Investment for development of therapies and vaccines of a oncology focused Louisiana Biotech Company. Facilitated Listing on OTC Markets using reverse merger resulting in Line of Credit (US$ 10mn).  Licensing of a dermal delivery system of an Australian company, applicable to both pharmaceutical and personal care products. Licensing Deals signed with 3 companies; Product launched with one; A few more deals in discussion.  Finding customers for Peptides API for a EU conglomerate. Orders received from 8 companies.  Out-Licensing & Distribution partnerships for an Ophthalmic Medical Device company. Signed with a major Pharma Company.  Creation and management of MSDS for a Fortune 100 Chemical company from Midwest US by striking alliance with the right partner in India. 85% Cost reduction was achieved within 6 months of starting operation. Few Examples of successes brought out to our clients: (Also see Case Studies for more details)
  7. 7. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Facilitating investment for development of targeted therapies and therapeutic vaccines • Investments and partnering to further develop its technologies and pipeline. 7 Louisiana based biotechnology company specializing in innovative cancer treatments • Aagami scanned the global market, identified right investors/ partners, and took them to 50 + companies. • With focused efforts 10+ companies had post CDA level scientific and clinical discussions. • Aagami kept facilitating and persevering, 3 companies moved to term sheet level discussions. • Finally Aagami found a right partner to facilitate reverse merger with a OTC Markets listed company. • This is enabling access to large sums of funds to develop clinical stage programs. • Listing on OTC Markets by a reverse merger • Financial resources to enable development of existing pipeline and technologies
  8. 8. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Establishing Partnerships for Development and Commercialisation of Novel Class of Protein Drugs • Innovator partners in India to collaborate on a new class of proteins - Anticalins® to develop various programs in Oncology and Ophthalmology. 8 German Biotech company making safer, effective and differentiated Novel drugs • Aagami identified right partners, and took them to 7 interested companies for Anticalins® • With focused efforts 3 companies moved to term sheet level discussions. Aagami kept facilitating and persevering. 2 companies remained for final negotiations. • Aagami maintained its spirits and perseverance knowing Indian ways of working; even when client was ready to give up as per Western ways. • Finally co development partnership happened in next few months with one company in Oncology. • Second company took more time and couple of visits before signing co-development deal for ophthalmic therapy. • Client signed co-development deals with 2 companies in Oct and Dec 2013 respectively • Right companies, right advice, structure, perseverance and commitment were the key success factor. in making it happen. • Aagami proved highly influential in negotiations for finalization of the deals due to deep experience in business culture nuances of India. • It brought repeat and referral business to Aagami.
  9. 9. 9 Sample list of Clients whom we have served USA CreAgri CA New Heaven Pharma CT Advangene IL Loyola Univ. Chicago IL OncBioMune LA Dow Chemicals MI ScyFIX MN Penwest Corp. NY DesignMedix OR DisperSol TX International UniTargetingResearch Norway PeptiSyntha Belgium DelMar Pharma Canada Affitech Denmark Pieris Germany Getinge Group Sweden Opsona Ireland Toppan Japan Otago University New Zealand Phosphagenics Australia Aagami has completed over 100 assignments for more than 50 clients in the last 13
  10. 10. 10 For your Success, we take this tested and proven Consulting Approach: Setup • Understand and capture important details about the asset/technology • Prepare ‘Elevator Pitch’ (EP) customized to specific business culture • Identify relevant companies from our database and resources Prospect • Broadcast EP to Relevant Companies • Follow-up with phone calls and emails • Coordinate CDAs with interested Companies • Supply further info through emails • Organize conference calls for clarifications Finalize • Organize Road show • Manage appointments with right executives • Coordinate the logistics of the road show • Advise on structuring the deal • Support in negotiations (most critical)
  11. 11. 11 Working with Aagami- Engagement Model  Dedicated Teamwork (40-80 Hours/month)  Small monthly ‘commitment’ fee for first 6 months  Success bonus  The gap between the commitment fee and a retainer, is our investment, in your company.  Aagami’s prime focus is CLIENT SUCCESS as that's how we Succeed
  12. 12. 12 Sample of Aagami contacts in India We have a working relationship at C Level of TOP 100 Lifesciences companies in India. Some of the popular names are below. Biocon Intas Sun Pharma Cadila Lupin Themis Cipla MicroLabs Torrent Pharma Dr Reddys Piramal USV Glenmark Reliance Wockhardt Hetero Drugs Strides Zydus
  13. 13. 13 Strategy Segment IN Licensing OUT Licensing M & A Partnership Co-Development Regulatory Market Research & Entry Supply Chain & Distribution BD Pharmaceuticals Biotechnology CRO & CRAMS Delivery Technology Diagnostics Consumer Health Products Nutraceuticals/ Cosmeceuticals Medical Device Labware Supported all Segments and Strategies The colored boxes represent our experience in that Sector and assignment completed in Strategic area
  14. 14. 14 Dinesh Jain, MBA – Founder CEO • A business leader in Science and technology industry since 1984 with global experience in starting and managing several technology companies. Has held positions of CEO, President, Vice President. Is a prolific entrepreneur. Has executed several dozen international deals across 4 continents. He is a regular speaker in International conference son Life Sciences Business with India, and also on board of several consulting and research companies Dr. Mahendra Shah, Ph D – Scientific & Business • A veteran Scientific leader in Bio-Pharmaceutical field since 1968 . After his PhD, he has worked with some of the top notch companies like Bristol, Squibb, Schering, Lyphomed, Fujisawa, EJ Financials, First Horizon, NextWave. Mahendra is an active Investor in BioPharmaceutical field and is on the Board of several companies across the country. Michael S. Rosen, MBA - Business • A Senior executive and entrepreneur working globally since 1974. Managed 3 multinational pharma and agro-science companies working in Europe, Latin America, Japan, Canada, Asia and Israel. CEO experience starting and growing several biotech and medical device companies in the U.S. and Europe, raising more than $50 million in equity and taking 1 company public. Economic development expertise creating and expanding vibrant science parks and life-science ecosystems as public-private partnerships Aagami Leadership Team 1 of 2
  15. 15. 15 Aagami Leadership Team 2 of 2 Dr. Aman Ahuja, M.D., F.P.M., F.R.C.A. – Medical • A specialist pain medicine physician and consultant at the North Queensland, Australia. MD Anaesthesia from India, Fellow of Royal College of Anaesthetists, Ireland, Masters in Pain Medicine from UK, Fellow of Tess Cramond Multidisciplinary Pain Centre, Australia; Dr. Ahuja has focus on clinical practice, research and advancing rational therapies for a diverse range of conditions. His current interests include studying the expanding role of radiofrequency in field of Pain Medicine. Dr. Ahuja uses a compassionate and multidisciplinary approach in his well known practice as a Pain Specialist and Anesthetist. Dr. Shridhar Andurkar, Ph D – Scientific • Chair and Associate Professor of Pharmaceutical sciences at Midwestern University, Chicago College of Pharmacy, is a Ph D from Auburn University in Medicinal Chemistry, Conducted postdoctoral research at the University of Houston. Dr. Andurkar has published numerous papers and made several presentations in this field. He holds a US patent in the area of anticonvulsant drugs and is on the advisory boards of several companies. Nancy Chew - Regulatory • A serial entrepreneur, veteran business leader, biochemist and Pharmacologist by education, Regulatory expert, Several top honors & award winner and Advisor to numerous Life Sciences companies. Nancy's accomplishments and achievements of over 39 years would take several pages to detail.
  16. 16. 16 Aagami Associate Partners Dr. Hemant Sabharwal M.D., Ph.D. – Founder - Laktobiotics •15 years of extensive global experience. Lived and worked in the Middle East, Egypt, Scandinavia, India, and the US. He is also Adjunct Faculty in Department of Medical Microbiology and Immunology, Streptococcal vaccine development, Rockefeller University, New York, NY. He has more than 20 publications in peer reviewed Medical and Scientific journals. He has worked with prestigious institutions such as Institute for Cancer Prevention, NY, Mount Sinai Medical Center, NY, Lund University, Sweden, MonoCarb AB, Sweden, BioCarb AB, Sweden Anant Kataria – Founder Partner, Sagacious Research •Anant's expertise lies in supporting Patent Practitioners/Consultants, Patent Licensing Firms/Executives, Law firms in US and Europe by providing a cost-effective back-end team for all their patent related needs. His work experience is a blend of Intellectual Property Research (IP) in various technical domains and R&D in Automobile Industry. Vyom Shah, MBA - Founder, Phronesis Strategies •Vyom has worked with companies such as PwC and TCS. With 9+ years of experience, he has extensively worked on several consulting and research cases including NPV valuations across diverse verticals and has served clients ranging from Fortune 500 companies to SMEs, supporting end-to-end engagement lifecycle. He holds an MBA from Lancaster University Management School, UK, specialising in Strategy and Management Consulting and is a qualified Chartered Accountant. Faiz Wahid, MBA - Co-founder, pManifold Research and Consulting •His company pManifold focuses on research, consulting and stakeholder engagement services. Under his leadership the firm has conducted over 15000+ primary customer interviews for various cross sector companies. He holds an MBA from HEC Paris and was also an international scholar at the Darden School of Business of the University of Virginia. He also holds a masters in engineering from BITS Pilani and bachelors in engineering from VNIT Nagpur.
  17. 17. 17 USA (Head Office) Aagami, Inc. 2135 City Gate Lane Suite 300 Naperville, IL 60653 P: +1-630-364-1837 INDIA Aagami 741, Nelson Square Nagpur MH 440013 P: +91-712-258-6678 Dinesh Jain Email: dinesh@aagami.com M: +1 630-853-3520 Godwyn Francis Email: godwyn@aagami.com M: +91-787-501-6957 www.aagami.com CONTACT
  18. 18. MARKET INTELLIGENCE through Business & Market Research
  19. 19. Offerings in Market/ Business Research Competitive Landscape Assessments Analysis of Portfolio and Opportunities identification Price Discovery Research Due Diligence IP and Regulatory Research Financial Modeling, NPV valuations New Market Entry strategy Market development strategy 19 Lifesciences Catalyst
  20. 20. Research Methodology Study/ Research •Primary •Interviews with different stakeholders in the Value chain including opinion leaders, vendors and customers •Proceedings of Industry events, press conferences and workshops •Surveys /studies •Secondary •Company websites, social media, blogs, forums and groups •Business directories and databases •Online and offline libraries and government data •Economic and Demographic information, Census •Case studies, Reference Customers, vendors, and associations Analysis •Qualitative •Policy and Regulatory environment •Competitive Landscape Assessment (CLA) •Business Analysis, Industry Analysis •Trends & Drivers, •Challenges and Risks •Quantitative •Market Sizing, Segmentation and Forecasting •Market share and Opportunity Analysis Reporting •Deliverables •Whitepapers •Industry Reports •Investment Models •Trend Reports •Tracking Reports •Competitive Report •Price Discovery Report •Corporate Profiles •Forecasts •Guesstimates •NPV Valuation •Client Presentation and clarifications on client questions Assess, Analyze, Derive, Synthesize, Report 20 Lifesciences Catalyst
  21. 21. SELECT CASE STUDIES  Strategic Consulting  Market Intelligence & Valuations Lifesciences Catalyst 21
  22. 22. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Technology Out-licensing of Transdermal Drug Delivery Technology with 3 Indian Companies  To Out-License TPM® Technology and Co-Develop in clinic products using proprietary Delivery technology and market such products in India and possibly larger region. 22 TPM® Technology and Products Company from Australia  Aagami scanned numerous companies and got 10 relevant companies interested.  Discussion with 8 companies progressed.  Took client to India 3 times for term sheet level meetings and deal signing.  Facilitated entire evaluation and deal structuring process  Aagami made sure testing and other protocols were honoured before deal was made.  During the process Aagami ensured clear understanding despite socio cultural differences in styles of working.  Deals with 3 global companies of India –The first deal was struck for diclofenac topical gel formulation containing TPM platform. The Indian partner not only launched their own product but also out licensed to a major western pharma. –The second alliance was struck for use in Skin Whitening and under eye cream. –Third deal - Aagami was able to facilitate a new business model with this prospect, who using client technology increased bio availability as well as stability of a specific antibiotic.
  23. 23. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Reducing cost of creation and management of MSDS Cost reduction for customized MSDS for various countries with unique regulations for thousands of chemicals it produces. 23 Fortune 100 Chemical company from Midwest US • Client is in Chemicals business for over 100 years across 150 countries and needed to create 1000s of MSDS every month. • This had become very expensive due to complexities and different regulatory needs of various countries . • Aagami analysed the situation and suggested offloading such processes to Indian companies • Aagami scanned though its database and network to identify the right partners. • Performed due diligence on the shortlisted agencies and facilitated discussions and influenced negotiations and deal structuring • Aagami helped strike alliance with the right partner in India. • 85% Cost reduction was achieved within 6 months of starting operation • The client continues to employ Global Delivery Model for MSDS creation and management
  24. 24. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Study of Market Potential and Prospective Partners in India for hand-held qPCR Diagnostic Device • Innovation center wanted to study the market potential in India for their innovative mobile, lightweight molecular diagnostic technology and device. • On Aagami’s suggestion, client agreed to include regulatory overview and potential partners in the study. 24 Innovation Center of a New Zealand University focused on Health Sciences • Aagami involved a team of a senior and a junior researcher to conduct secondary and primary research to assess and collect market data. • Identified Competitors and their product ranges and also did a brief comparison analysis. • Prepared a crisp and concise report with data, analysis and recommendations • Also prepared a regulatory overview document • Captured the potential end users of the product as well as shortlisted potential partners • Offered consulting support for Partnership Development and India Market Entry with a clearly defined Partnering Strategy and roadmap to achieve the goal. • The report helped the University in determining conclusively on India market initiative. • Pleased with the report, the University appointed Aagami to find a licensing partner in India
  25. 25. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Global NPV of Technology (in USD Million) (P) Pessimistic Scenario Discount rate 8.60% Year 2012 2013 2014 2015 2016 2017 2018 Time 0 1 2 3 4 5 6 Revenue from Sale of NPTP POC devices - - 20.30 23.62 32.06 40.80 24.93 Revenue from Sale of Treated Cuvette - - 450.00 614.87 815.48 1,021.15 657.19 Total Cost of NPTP POC devices - - 4.10 5.66 7.69 9.78 5.98 Total Cost of Treated Cuvettes - - 175.00 387.88 514.43 644.17 414.57 Commercialisation Costs 400.00 - - - - - - Total Cash Inflow - - 470.30 638.49 847.54 1,061.96 682.11 Total cash Outflow 400.00 - 179.10 393.54 522.12 653.96 420.55 Net Cash Flow -400.00 - 291.20 244.95 325.43 408.00 261.56 Discount Factor 1.00 0.92 0.85 0.78 0.72 0.66 0.61 Discounted Cash Flow -400.00 - 246.91 191.24 233.96 270.09 159.44 NPV 1,524.77 Assessment of Global Net Present Value (NPV) of a revolutionary Nanotechnology Based Diagnostic Platform • Client wanted to commercialize ground breaking technology in the MI Diagnostics field, and wanted to know its commercial potential so that suitable licensing fees and model could be determined and also value could be showcased to Licensees 25 Investors Controlled Innovative technology company • Aagami involved a team of a senior consultant part time and a business analyst full time to conduct primary and secondary research involving domain specialists to capture current market scenario. • Performed competitive benchmarking to assess a Relative Cost Benefit Index used later for determining technology platform (product) pricing. • Projected annual demand for next ten years in three different scenarios - Median, Optimistic and Pessimistic across multiple disease categories. • Forecasted Global Average Selling Price (ASP) and Cost associated with capex and opex • Validated commercializing options and measured incremental financial scenario for potential licensees • Determined the Global Net Present Value (NPV) and created Financial models • NPV of the technology and indicative licensing fees, along with several insights generated, served as conclusive guidance to the client for deal-making and negotiations. • The client was delighted which also resulted in repeat assignments
  26. 26. Case Study Client Client Need Solution Approach Results **Data has been sanitized and meant for Illustrative purposes only Competitive Landscape Analysis in India to finalize Pricing strategy of high-end Cosmeceuticals • Client, a public limited company in Australia needed to get a competitive landscape of prestige skin whitening, anti-ageing and body shaping market in India, to order to device strategy on their pricing and licensing for Indian Market 26 Publicly Listed Australian skincare products & technology company • Aagami involved a team of a senior and a junior researcher part time to conduct secondary research on web and primary research via in person visits to shops, mall and interviews with Industry professionals, Business owners, store managers, salon managers and doctors to assess market and collect data • Identified Competitors and their product ranges with their Price points and feedback from stakeholders • Prepared a crisp and concise report with data, analysis and Unit Price Map in MS- Excel format in an easy to understand and customized views. • Performed competitive benchmarking to assess a Relative Cost Benefit Index and recommended potential product pricing ranges. • As per client, the report was extremely helpful and enlightening in preparing for their trip to India, and proved essential in determining conclusively whether their product range is capable of selling in the Indian market at the equivalent of Australian retail prices
  27. 27. Aagami Factsheet 27 50+ Clients 100+ Assignments Large ‘C’ level network 20+ deals USD 500+ mn Cross border deals, Investments Multi- geographic presence 150+yrs Experience Aagami Team Global experience Client Success – most important

×